Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Subjects With Alcohol Use Disorder (AUD)

NCT05913752 is registered in ClinicalTrials.gov with Clearmind Medicine Inc. as lead sponsor.

NCT NCT05913752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05913752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Subjects With Alcohol Use Disorder (AUD)
Lead sponsor
Clearmind Medicine Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 30, 2025
Completion date
December 31, 2026
Enrollment
84 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder